However, there are clinical circumstances in which a risk–benefit assessment may favor treatment, and some data suggest that certain transplant recipients will benefit from treatment with IFN monotherapy or IFN plus
ribavirin combination therapy (Table 3) (71,72,102–105). For example,
HCV-associated glomerulonephritides can recur after kidney transplantation and cause progressive renal dysfunction, and antiviral therapy may be needed to prevent graft loss (106,107).